Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02505269 | Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04514081 | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. | unknown | Phase 2 | 200 | Chinese PLA General HospitalOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | terminated | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02875067 | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04233294 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | unknown | Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01921387 | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT03474133 | Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)(BASALT) | unknown | Phase 2 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 21, 2020 | clinicaltrials |
| NCT04464590 | Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT(LYMPHOTEP1) | completed | — | 100 | University Hospital, BrestOTHER | 0 | Jul 9, 2020 | clinicaltrials |
| NCT01217229 | Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 20 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT03042247 | Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma | unknown | — | 120 | Marco PicardiOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT00062868 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma(ALCI) | completed | Phase 1 | 74 | Baylor College of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT03343652 | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma(NB001) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02624258 | Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma | terminated | Early Phase 1 | 2 | University of PennsylvaniaOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT02003625 | Meloxicam vs Placebo for Mobilization | completed | Phase 2 | 31 | Massachusetts General HospitalOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02603419 | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | terminated | Phase 1 | 34 | PfizerINDUSTRY | 3 | Apr 24, 2020 | clinicaltrials |
| NCT01611298 | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR(TAR) | completed | N/A | 7 | Robert KranceOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT00967369 | Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT00002561 | Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease | completed | Phase 3 | 405 | NCIC Clinical Trials GroupNETWORK | 3 | Apr 14, 2020 | clinicaltrials |
| NCT00566696 | Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | completed | Phase 2 | 73 | St. Jude Children's Research HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00082888 | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2020 | clinicaltrials |
| NCT01356680 | HD17 for Intermediate Stage Hodgkin Lymphoma | completed | Phase 3 | 1,100 | University of CologneOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02164500 | JAK-inhibition in Recurrent Classical Hodgkin Lymphoma(JeRiCHO) | completed | Phase 2 | 12 | University of CologneOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | terminated | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04298619 | Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission(HOLYFU) | completed | — | 123 | Federico II UniversityOTHER | 0 | Mar 6, 2020 | clinicaltrials |
| NCT00654732 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | completed | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01447056 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases(MALTED) | completed | Phase 1 | 37 | Baylor College of MedicineOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00096161 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT03343665 | Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma(Nivo40) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT04239170 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 84 | Peking UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00343564 | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 68 | CytokineticsINDUSTRY | 2 | Jan 13, 2020 | clinicaltrials |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | completed | Phase 1 / Phase 2 | 119 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 73 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT03471351 | Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL | terminated | Phase 1 | 2 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 24, 2020source: clinicaltrials